Business Context and Reporting Period
This Form 8-K is a current report filed by Obalon Therapeutics, Inc. (not Vyome Holdings, Inc.) on January 17, 2017, regarding events occurring on January 12, 2017. The filing discloses the appointment of a new director to the Company's Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to director compensation:
- Annual Cash Retainer: $35,000
- Stock Option Grant: 105,128 shares
- Exercise Price: $9.23 per share
- Vesting Schedule: Monthly over three years
Material Changes
The material change reported is the appointment of Jonah Shacknai as a Class III director, effective January 12, 2017. This appointment includes a standard indemnification agreement and the equity compensation package detailed above.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states there are no undisclosed arrangements or material interests related to the appointment.
Investor Verification Checklist
- Verify the correct registrant name is Obalon Therapeutics, Inc., not Vyome Holdings, Inc.
- Confirm the vesting terms of the 105,128 stock options granted to the new director.
- Review the Company's existing compensation policy for non-employee directors to validate the $35,000 retainer.
- Check the Form S-1 filed on September 26, 2016, for the standard indemnification agreement referenced in this filing.